Kind Pharmaceuticals is a global biotechnology company developing pan-anemia and oncology therapies led by clinical HIF stabilizer AND017.
en.kindpharma.comCrawled Nov 12, 2026
KIND Pharmaceuticals presents preclinical data for **AND017**, showing efficacy in **Townes Sickle Cell Disease (SCD) mouse models**, **inducible Mutant c-Myc Knock-in myelodysplastic syndromes (MDS) models**, and **Hbbd3th β-thalassemia mouse models**. The company also announces **FDA authorization of an Investigational New Drug (IND) application**, enabling clinical trials for AND017 in **Sickle Cell Disease (SCD)**.
KIND reports positive Phase II and Phase I clinical trial results for **AND017**, a treatment targeting anemia in patients with chronic kidney disease (CKD). The findings were presented at the **American Society of Nephrology (ASN) Kidney Week 2024**. The drug candidate shows potential as a novel therapeutic approach for managing anemia in CKD patients.
Kind Pharmaceuticals receives FDA Orphan Drug Designation for its experimental therapy **AND017**, targeting **sickle cell disease (SCD)**. The designation supports development of the drug, which is in clinical-stage trials for hematological disorders. Kind Pharmaceuticals, a biopharmaceutical company, focuses on innovative treatments for blood-related diseases and cancers.
Kind Pharmaceutical presents late-breaking findings from its **AND017 Phase 2 clinical trial** evaluating a treatment for anemia in dialysis-dependent chronic kidney disease (DD-CKD) at **ASN Kidney Week 2024**. The abstract covers trial results targeting anemia, a common complication in advanced CKD patients. Kind Pharmaceutical, a clinical-stage biopharmaceutical company, specializes in hematological disease therapies.
Kind Pharmaceuticals and its executives, Dr. Dong Liu and Dr. Shaojiang Deng, settle a legal dispute with FibroGen regarding its hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) technology. The agreement includes the withdrawal of all pending litigation between the parties. The settlement resolves claims related to intellectual property rights over the HIF-PHI technology platform.